An official website of the United States government
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Trial Status: active
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene
autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and
elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Inclusion Criteria
History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
Measurable multiple myeloma (MM).
Eastern Cooperative Oncology Group performance status of 0-1.
Exclusion Criteria
Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
Prior treatment with GPRC5D-targeting therapies. Note: Other protocol-defined inclusion/exclusion criteria apply
Additional locations may be listed on ClinicalTrials.gov for NCT06121843.
Locations matching your search criteria
United States
Alabama
Birmingham
University of Alabama at Birmingham Cancer Center
Status: Active
Name Not Available
Arizona
Scottsdale
Mayo Clinic in Arizona
Status: Active
Name Not Available
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Florida
Jacksonville
Mayo Clinic in Florida
Status: Active
Name Not Available
Georgia
Atlanta
Emory University Hospital/Winship Cancer Institute
Status: Approved
Name Not Available
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: Active
Name Not Available
Massachusetts
Boston
Dana-Farber Cancer Institute
Status: Active
Name Not Available
Brigham and Women's Hospital
Status: Active
Name Not Available
Beth Israel Deaconess Medical Center
Status: Active
Name Not Available
Minnesota
Rochester
Mayo Clinic in Rochester
Status: Active
Name Not Available
Nebraska
Omaha
University of Nebraska Medical Center
Status: Active
Name Not Available
New Jersey
Hackensack
Hackensack University Medical Center
Status: Active
Name Not Available
New York
Buffalo
Roswell Park Cancer Institute
Status: Active
Name Not Available
New York
Memorial Sloan Kettering Cancer Center
Status: Active
Name Not Available
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Status: Active
Name Not Available
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Status: Active
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
Trial PhasePhase I
Trial Typetreatment
Lead OrganizationJuno Therapeutics, Inc., a Bristol-Myers Squibb Company
